{
  "input": {
    "mode": "report_and_evolve",
    "query": {
      "entity": "Generalised pustular psoriasis",
      "relation": "indication"
    },
    "hypotheses": [
      {
        "id": "H1",
        "candidate": {
          "id": "drug_acitretin",
          "name": "Acitretin"
        },
        "mechanism_outline": "",
        "priority": 1.0
      },
      {
        "id": "H2",
        "candidate": {
          "id": "drug_ciclosporin",
          "name": "Ciclosporin"
        },
        "mechanism_outline": "",
        "priority": 0.95
      },
      {
        "id": "H3",
        "candidate": {
          "id": "drug_methotrexate",
          "name": "Methotrexate"
        },
        "mechanism_outline": "",
        "priority": 0.9
      },
      {
        "id": "H4",
        "candidate": {
          "id": "drug_ustekinumab",
          "name": "Ustekinumab"
        },
        "mechanism_outline": "",
        "priority": 0.85
      },
      {
        "id": "H5",
        "candidate": {
          "id": "drug_secukinumab",
          "name": "Secukinumab"
        },
        "mechanism_outline": "",
        "priority": 0.8
      },
      {
        "id": "H6",
        "candidate": {
          "id": "drug_infliximab",
          "name": "Infliximab"
        },
        "mechanism_outline": "",
        "priority": 0.75
      },
      {
        "id": "H7",
        "candidate": {
          "id": "drug_etanercept",
          "name": "Etanercept"
        },
        "mechanism_outline": "",
        "priority": 0.7
      },
      {
        "id": "H8",
        "candidate": {
          "id": "drug_tildrakizumab",
          "name": "Tildrakizumab"
        },
        "mechanism_outline": "",
        "priority": 0.6499999999999999
      },
      {
        "id": "H9",
        "candidate": {
          "id": "drug_apremilast",
          "name": "Apremilast"
        },
        "mechanism_outline": "",
        "priority": 0.6
      },
      {
        "id": "H10",
        "candidate": {
          "id": "drug_brodalumab",
          "name": "Brodalumab"
        },
        "mechanism_outline": "",
        "priority": 0.55
      },
      {
        "id": "H11",
        "candidate": {
          "id": "drug_guselkumab",
          "name": "Guselkumab"
        },
        "mechanism_outline": "",
        "priority": 0.5
      },
      {
        "id": "H12",
        "candidate": {
          "id": "drug_risankizumab",
          "name": "Risankizumab"
        },
        "mechanism_outline": "",
        "priority": 0.44999999999999996
      }
    ],
    "scores": [
      {
        "hypothesis_id": "H1",
        "score": 0.78,
        "components": {
          "mechanism_fit": 0.9,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.7,
          "indication_plausibility": 0.8,
          "safety_risk": 0.2,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.05
        },
        "graph_signals": {
          "support_weight": 0.85,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": true,
          "path_disjointness": 3,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Acitretin 作用于 Th17 通路，与广泛性脓疱型银屑病相关的炎症机制吻合"
          ]
        },
        "confidence": "high"
      },
      {
        "hypothesis_id": "H2",
        "score": 0.83,
        "components": {
          "mechanism_fit": 0.85,
          "class_prior": 0.7,
          "pk_pd_feasibility": 0.75,
          "indication_plausibility": 0.75,
          "safety_risk": 0.25,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.02
        },
        "graph_signals": {
          "support_weight": 0.85,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": true,
          "path_disjointness": 3,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Ciclosporin 的免疫调节作用与广泛性脓疱型银屑病的治疗相关"
          ]
        },
        "confidence": "high"
      },
      {
        "hypothesis_id": "H3",
        "score": 0.76,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.7,
          "indication_plausibility": 0.7,
          "safety_risk": 0.15,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.04
        },
        "graph_signals": {
          "support_weight": 0.7,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Methotrexate 通过免疫抑制改善广泛性脓疱型银屑病症状"
          ]
        },
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H4",
        "score": 0.8,
        "components": {
          "mechanism_fit": 0.9,
          "class_prior": 0.75,
          "pk_pd_feasibility": 0.75,
          "indication_plausibility": 0.8,
          "safety_risk": 0.1,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.0
        },
        "graph_signals": {
          "support_weight": 0.9,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": true,
          "path_disjointness": 3,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Ustekinumab 靶向 IL-23，干预 Th17 反应，与广泛性脓疱型银屑病相关"
          ]
        },
        "confidence": "high"
      },
      {
        "hypothesis_id": "H5",
        "score": 0.79,
        "components": {
          "mechanism_fit": 0.85,
          "class_prior": 0.75,
          "pk_pd_feasibility": 0.7,
          "indication_plausibility": 0.75,
          "safety_risk": 0.15,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.03
        },
        "graph_signals": {
          "support_weight": 0.85,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": true,
          "path_disjointness": 3,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Secukinumab 直接抑制 IL-17，适用于广泛性脓疱型银屑病治疗"
          ]
        },
        "confidence": "high"
      },
      {
        "hypothesis_id": "H6",
        "score": 0.77,
        "components": {
          "mechanism_fit": 0.8,
          "class_prior": 0.75,
          "pk_pd_feasibility": 0.75,
          "indication_plausibility": 0.7,
          "safety_risk": 0.1,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.02
        },
        "graph_signals": {
          "support_weight": 0.7,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": true,
          "path_disjointness": 2,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Infliximab 作为 TNF-α 抑制剂，减缓广泛性脓疱型银屑病的炎症反应"
          ]
        },
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H7",
        "score": 0.74,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.7,
          "pk_pd_feasibility": 0.7,
          "indication_plausibility": 0.65,
          "safety_risk": 0.2,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.03
        },
        "graph_signals": {
          "support_weight": 0.7,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Etanercept 在炎症控制方面可能有效，但与广泛性脓疱型银屑病的直接关联欠缺"
          ]
        },
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H8",
        "score": 0.75,
        "components": {
          "mechanism_fit": 0.75,
          "class_prior": 0.65,
          "pk_pd_feasibility": 0.7,
          "indication_plausibility": 0.7,
          "safety_risk": 0.15,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.03
        },
        "graph_signals": {
          "support_weight": 0.7,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Tildrakizumab 的作用与 IL-23 的靶向一致，显示出对广泛性脓疱型银屑病的可能疗效"
          ]
        },
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H9",
        "score": 0.72,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.65,
          "indication_plausibility": 0.65,
          "safety_risk": 0.1,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.03
        },
        "graph_signals": {
          "support_weight": 0.6,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Apremilast 通过磷酸二酯酶4抑制发挥免疫作用，但与疾病的直接联系需进一步研究"
          ]
        },
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H10",
        "score": 0.71,
        "components": {
          "mechanism_fit": 0.65,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.65,
          "indication_plausibility": 0.65,
          "safety_risk": 0.1,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.02
        },
        "graph_signals": {
          "support_weight": 0.6,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Brodalumab 对 IL-17 的靶向作用显示出潜在效用，但整体证据相对较少"
          ]
        },
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H11",
        "score": 0.74,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.65,
          "pk_pd_feasibility": 0.65,
          "indication_plausibility": 0.65,
          "safety_risk": 0.1,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.02
        },
        "graph_signals": {
          "support_weight": 0.6,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Guselkumab 的 IL-23 靶点对广泛性脓疱型银屑病具有相关性，但证据量需加强"
          ]
        },
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H12",
        "score": 0.7,
        "components": {
          "mechanism_fit": 0.65,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.65,
          "indication_plausibility": 0.65,
          "safety_risk": 0.1,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.03
        },
        "graph_signals": {
          "support_weight": 0.6,
          "contradiction_weight": 0.0,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Risankizumab 作为 IL-23 抑制剂与广泛性脓疱型银屑病的治疗相关，但证据需进一步支持"
          ]
        },
        "confidence": "medium"
      }
    ],
    "ranking": [
      "H2",
      "H4",
      "H5",
      "H1",
      "H6",
      "H3",
      "H8",
      "H7",
      "H11",
      "H9",
      "H10",
      "H12"
    ],
    "tegraph_snapshot": {
      "nodes": [
        {
          "id": "n_acitretin",
          "type": "Drug",
          "label": "Acitretin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_ciclosporin",
          "type": "Drug",
          "label": "Ciclosporin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_ustekinumab",
          "type": "Drug",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_secukinumab",
          "type": "Drug",
          "label": "Secukinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_infliximab",
          "type": "Drug",
          "label": "Infliximab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_etanercept",
          "type": "Drug",
          "label": "Etanercept",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_tildrakizumab",
          "type": "Drug",
          "label": "Tildrakizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_apremilast",
          "type": "Drug",
          "label": "Apremilast",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_brodalumab",
          "type": "Drug",
          "label": "Brodalumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_guselkumab",
          "type": "Drug",
          "label": "Guselkumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_risankizumab",
          "type": "Drug",
          "label": "Risankizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_gp_psoriasis",
          "type": "Disease",
          "label": "Generalised pustular psoriasis",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_th17_pathway",
          "type": "Pathway",
          "label": "Th17 pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_immunomodulation",
          "type": "Pathway",
          "label": "Immunomodulation pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_inflammation",
          "type": "Phenotype",
          "label": "Inflammation",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_skin_flare",
          "type": "Phenotype",
          "label": "Skin Flare",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H1",
          "type": "Hypothesis",
          "label": "Acitretin",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_acitretin",
          "type": "Drug",
          "label": "Acitretin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H2",
          "type": "Hypothesis",
          "label": "Ciclosporin",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_ciclosporin",
          "type": "Drug",
          "label": "Ciclosporin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H3",
          "type": "Hypothesis",
          "label": "Methotrexate",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H4",
          "type": "Hypothesis",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_ustekinumab",
          "type": "Drug",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H5",
          "type": "Hypothesis",
          "label": "Secukinumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_secukinumab",
          "type": "Drug",
          "label": "Secukinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H6",
          "type": "Hypothesis",
          "label": "Infliximab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_infliximab",
          "type": "Drug",
          "label": "Infliximab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H7",
          "type": "Hypothesis",
          "label": "Etanercept",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_etanercept",
          "type": "Drug",
          "label": "Etanercept",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H8",
          "type": "Hypothesis",
          "label": "Tildrakizumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_tildrakizumab",
          "type": "Drug",
          "label": "Tildrakizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H9",
          "type": "Hypothesis",
          "label": "Apremilast",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_apremilast",
          "type": "Drug",
          "label": "Apremilast",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H10",
          "type": "Hypothesis",
          "label": "Brodalumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_brodalumab",
          "type": "Drug",
          "label": "Brodalumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H11",
          "type": "Hypothesis",
          "label": "Guselkumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_guselkumab",
          "type": "Drug",
          "label": "Guselkumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "H12",
          "type": "Hypothesis",
          "label": "Risankizumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "drug_risankizumab",
          "type": "Drug",
          "label": "Risankizumab",
          "attrs": {
            "agent": "Proponent"
          }
        }
      ],
      "edges": [
        {
          "source": "n_acitretin",
          "target": "n_th17_pathway",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "已知促发Th17细胞网络"
        },
        {
          "source": "n_ciclosporin",
          "target": "n_immunomodulation",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "免疫调节作用支持"
        },
        {
          "source": "n_methotrexate",
          "target": "n_immunomodulation",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "通过免疫抑制改善病症"
        },
        {
          "source": "n_ustekinumab",
          "target": "n_th17_pathway",
          "relation": "acts_on",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "靶向IL-23，干预Th17反应"
        },
        {
          "source": "n_secukinumab",
          "target": "n_th17_pathway",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "直接抑制IL-17"
        },
        {
          "source": "n_infliximab",
          "target": "n_immunomodulation",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "TNF-α抑制剂，对应炎症"
        },
        {
          "source": "n_etanercept",
          "target": "n_immunomodulation",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "也为TNF-α抑制剂"
        },
        {
          "source": "n_tildrakizumab",
          "target": "n_th17_pathway",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "靶向IL-23，减轻症状"
        },
        {
          "source": "n_apremilast",
          "target": "n_immunomodulation",
          "relation": "acts_on",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "磷酸二酯酶4抑制剂，有助于控制炎症"
        },
        {
          "source": "n_brodalumab",
          "target": "n_th17_pathway",
          "relation": "acts_on",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "靶向IL-17的单抗及其作用机制"
        },
        {
          "source": "n_guselkumab",
          "target": "n_th17_pathway",
          "relation": "acts_on",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "靶向IL-23相关机制"
        },
        {
          "source": "n_risankizumab",
          "target": "n_th17_pathway",
          "relation": "acts_on",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "针对IL-23的作用"
        },
        {
          "source": "n_th17_pathway",
          "target": "n_inflammation",
          "relation": "involved_in",
          "weight": 0.87,
          "agent": "Proponent",
          "rationale": "与炎症表型直接相关"
        },
        {
          "source": "n_inflammation",
          "target": "n_gp_psoriasis",
          "relation": "associated_with",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "炎症与广泛性脓疱型银屑病直接相关"
        },
        {
          "source": "n_immunomodulation",
          "target": "n_skin_flare",
          "relation": "involved_in",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "调节免疫反应对皮肤反应影响"
        },
        {
          "source": "n_skin_flare",
          "target": "n_gp_psoriasis",
          "relation": "associated_with",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "皮肤反应与疾病的临床表现一致"
        }
      ],
      "round_index": 4
    },
    "history": {
      "round": 4
    },
    "thresholds": {
      "stop_delta": 0.03,
      "saturation_ratio": 0.65,
      "weights": {
        "path_disjointness": 1.0
      }
    },
    "ablation_config": {
      "enable_debate": true,
      "enable_skeptic": true,
      "enable_pi_interrupts": true,
      "enable_textual_feedback": true,
      "enable_heuristic_transfer": true,
      "enable_seed_regen": true,
      "weights": {
        "path_disjointness": 1.0
      },
      "mode": "graph"
    }
  },
  "output": {
    "final_recommendations": [
      {
        "hypothesis_id": "H2",
        "candidate": {
          "id": "drug_ciclosporin",
          "name": "Ciclosporin"
        },
        "score": 0.83,
        "graph_snapshot_ref": "GE_H2_round5",
        "key_assumptions": [
          "Ciclosporin 的免疫调节作用有效",
          "与广泛性脓疱型银屑病相关通路的连通性"
        ],
        "caveats": [
          "个体对药物的反应差异可能影响疗效"
        ],
        "confidence": "high"
      },
      {
        "hypothesis_id": "H4",
        "candidate": {
          "id": "drug_ustekinumab",
          "name": "Ustekinumab"
        },
        "score": 0.8,
        "graph_snapshot_ref": "GE_H4_round5",
        "key_assumptions": [
          "靶向 IL-23 的机制已被证实有效",
          "阐明了与 Th17 反应相关的治疗机制"
        ],
        "caveats": [
          "长期效果和安全性仍需评估"
        ],
        "confidence": "high"
      },
      {
        "hypothesis_id": "H5",
        "candidate": {
          "id": "drug_secukinumab",
          "name": "Secukinumab"
        },
        "score": 0.79,
        "graph_snapshot_ref": "GE_H5_round5",
        "key_assumptions": [
          "直接抑制 IL-17 机制的有效性",
          "对炎症反应的及时干预"
        ],
        "caveats": [
          "安全性评估仍需持续进行"
        ],
        "confidence": "high"
      }
    ],
    "audit_report": {
      "decisive_graph_motifs": [
        {
          "pattern": "Drug→Th17 pathway→Inflammation→Generalised pustular psoriasis",
          "reason": "展示了候选药物如何通过操控 Th17 通路而影响病症"
        }
      ],
      "remaining_gaps": [
        "部分药物的具体作用机制需进一步明确"
      ]
    },
    "seed_retrospective": {
      "batches": [],
      "lessons": []
    },
    "prompt_patches": [
      {
        "role": "Proponent",
        "patch": "集中于阐明药物机制与疾病表型间的直接关系，支持治疗效果的论证。"
      },
      {
        "role": "Skeptic",
        "patch": "对每种药物的安全性进行更多的临床证据收集以确认风险与效益。"
      },
      {
        "role": "Explorer",
        "patch": "建议关注更加广泛且多样化的药物作用机制，确保覆盖所有可能的治疗方案。"
      }
    ],
    "heuristics": [
      {
        "when": "广泛性脓疱型银屑病",
        "then": "优先考虑靶向 Th17 途径的药物，评估其在急性与慢性病程中的适用性"
      }
    ]
  }
}